APA (7th ed.) Citation

Gough, S. C. L., Bode, B., Woo, V., Rodbard, H. W., Linjawi, S., Poulsen, P., . . . Buse, J. B. (2014). Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: Results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naive patients with type 2 diabetes. The lancet. Diabetes & endocrinology, 2(11), 885-893. https://doi.org/10.1016/S2213-8587(14)70174-3

Chicago Style (17th ed.) Citation

Gough, Stephen C L., Bruce Bode, Vincent Woo, Helena W. Rodbard, Sultan Linjawi, Pernille Poulsen, Lars H. Damgaard, and John B. Buse. "Efficacy and Safety of a Fixed-ratio Combination of Insulin Degludec and Liraglutide (IDegLira) Compared with Its Components Given Alone: Results of a Phase 3, Open-label, Randomised, 26-week, Treat-to-target Trial in Insulin-naive Patients with Type 2 Diabetes." The Lancet. Diabetes & Endocrinology 2, no. 11 (2014): 885-893. https://doi.org/10.1016/S2213-8587(14)70174-3.

MLA (9th ed.) Citation

Gough, Stephen C L., et al. "Efficacy and Safety of a Fixed-ratio Combination of Insulin Degludec and Liraglutide (IDegLira) Compared with Its Components Given Alone: Results of a Phase 3, Open-label, Randomised, 26-week, Treat-to-target Trial in Insulin-naive Patients with Type 2 Diabetes." The Lancet. Diabetes & Endocrinology, vol. 2, no. 11, 2014, pp. 885-893, https://doi.org/10.1016/S2213-8587(14)70174-3.